MBF Therapeutics
Ambler, US
Biotech
Founders & leadership
CM
Christopher M. CashmanDirector
TT
Thomas TillettExecutive Officer, Director
Reported raises · per SEC filings
Form D private placements$105KraisedJan 2024 · 6 investors · Biotechnology
Rule 506(b)$814.3KraisedSep 2021 · 21 investors · Biotechnology
Rule 506(b)$605KraisedMay 2019 · 16 investors · Biotechnology
Rule 506(b)$1.1MraisedNov 2016 · 14 investors · Biotechnology
Rule 506(b)Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.